Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Rademikibart Phase 2 Study for Acute Asthma Exacerbations Transcript

Connect Biopharma Holdings Limited ( CNTB ) Discusses Topline Results of Rademikibart Phase 2 Study for Acute Asthma Exacerbations September 15, 2026 8:00 AM EDT Company Participants David Szekeres - President Barry Quart - CEO & Director Kimberly Manhard - Executive VP & Chief Development Officer Conference Call Participants Biren Amin - Piper Sandler & Co., Research Division Julian Harrison - BTIG, LLC, Research Division Olivia Saunders Thomas Smith - Leerink Partners LLC, Research Division Edward Nash - Canaccord Genuity Corp., Research Division Byunghyun Ahn - Oppenheimer & Co. Inc., Research Division Thomas Flaten - Lake Street Capital Markets, LLC, Research Division Presentation Operator Good day, ladies and gentlemen. Thank you for standing by. Welcome to the Connect Biopharma Conference Call. [Operator Instructions] Please be advised that today's conference may be recorded. I would now like to hand the conference over to your first speaker, David Szekeres, President of Connect Biopharma. Please go ahead, sir. David Szekeres President Thank you, operator. Good morning, everyone, and thank you for joining us. With me today from Connect are Barry Quart, Chief Executive Officer and Director; and Kimberly Manhard, Executive Vice President, Chief Development Officer. For those of you participating via conference call, the slides are made available via webcast and can be accessed by going to the Investor Relations page of our website following the conclusion of today's call. Before we begin, I would like to remind you that this call will contain forward-looking statements under applicable securities laws. These statements involve substantial risks and uncertainties and include statements concerning the top line results we are announcing today, the timing and content of additional data analysis and future data presentations, our anticipated regulatory strategy, interactions with the FDA and other health authorities, the design, initiation, timing and results of future clinical trials, our cash runway and anticipated use of capital and our future expectations, plans, prospects, corporate strategy and performance.